To explore the relationship of sleep duration and insomnia with muscle mass, strength, and quality in Chinese adults. Based on the second resurvey of China Kadoorie Biobank (CKB) in 2013-2014, logistic regression models were used to analyze the correlation of sleep duration, insomnia, and its duration with low muscle mass, handgrip strength, and muscle quality. The average sleep duration of the study population was (7.4±1.5) hours. Morbidities of short sleep duration (<6 hours), long sleep duration (≥9 hours), and insomnia were 9.3%,17.4%,and 29.9%,respectively. Compared with those who slept for 7- hours, those who slept for ≥9 hours were more likely to have low muscle mass, low handgrip strength,and low arm muscle quality (AMQ), and the (95%) of low appendicular skeletal muscle mass index (ASMI), low total skeletal muscle mass index (TSMI), low grip strength and low AMQ were 1.32 (1.18-1.48),1.26 (1.13-1.41), 1.33 (1.18-1.49) and 1.16 (1.03-1.30), respectively. Compared with participants without insomnia, insomnia patients were more likely to have low muscle mass,and the longer the duration of insomnia,the higher the risk ( for trend <0.001). Participants who reported <6 hours sleep duration and insomnia had a higher proportion of low ASMI and low TSMI,compared with those who slept for 7- hours and without insomnia, the (95%) were 1.26 (1.08-1.47) and 1.25 (1.07-1.46), respectively. Participants who reported ≥9 hours sleep duration were more likely to have low muscle mass,low handgrip strength,and low AMQ. Participants with insomnia had lower muscle mass, and the longer the duration of insomnia, the higher the proportion of low ASMI and low TSMI.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3760/cma.j.cn112338-20201020-01252 | DOI Listing |
Alzheimers Dement
December 2024
Newcastle University, Newcastle, Newcastle Upon Tyne, United Kingdom.
Background: HIV-associated neurocognitive disorders (HAND) are prevalent complications of ageing with treated HIV, disproportionally affecting sub-Saharan Africa. Causal HAND treatments are lacking worldwide; therefore, reversible factors are important to explore. Sleep duration and quality are frequently associated with risk of cognitive impairments.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of California, Irvine, Irvine, CA, USA.
Background: Family caregivers of persons with dementia (PWD) suffer from constant caregiving burden resulting in poor sleep quality. Understanding sleep parameters (e.g.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
West China Hospital of Sichuan University, Chengdu, China.
Background: Older adults with cognitive impairments will benefit from multicomponent interventions include cognitive training, exercise, and lifestyle modifications. Many digital therapeutic products predominantly focus on computerized cognitive training, lacking effective approaches to other crucial interventions. This study aimed to investigate the long term effects of multidimensional comprehensive cognitive intervention training program - Brain and Body Rehab Training (BBRT), which integrates multidomain cognitive training with physical-cognitive training and multidimensional lifestyle interventions on cognitive performance in participants with cognitive impairment after a 8-month follow-up.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Virginia, Charlottesville, VA, USA.
Background: Prior research on factors associated with sleep problems among care partners (CPs) of persons with cognitive decline (PwCD) are often limited by imprecise (i.e., single yes/no questions) measures of insomnia, burden, and CP mental health.
View Article and Find Full Text PDFImmunotherapy
January 2025
Blauvelt Consulting, LLC, Lake Oswego, OR, USA.
Aim: Lebrikizumab is an interleukin (IL)-13 inhibitor that specifically blocks IL-13 signaling. Here, we report the effects of lebrikizumab on asthma serum biomarkers in 2 phase 3 clinical studies.
Methods: LAVOLTA I and LAVOLTA II are replicate, double-blind, placebo-controlled trials with 52-week placebo-controlled treatment periods that evaluated lebrikizumab 37.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!